Slobodan Maricic

Dr. Slobodan Maricic

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 January 2021 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
SMSlobodan Maricic
Slobodan Maricic
AMAljosa Mandic
Aljosa Mandic
NDNinoslav Dejanovic
Ninoslav Dejanovic
NKNebojša Kladar
Nebojša Kladar
MKMarina of Popovic Krneta
Marina of Popovic Krneta
DKDunja Kokanov
Dunja Kokanov
Background/Aim. The gold standard in treating the advanced ovarian cancer (AOC) is primary debulking surgery (PDS) followed by platinum-based adjuvant chemotherapy. In the AOC, the extent of tumor resection (residual tumor volume) is the most important prognostic factor for overall survival (OS) and progression-free survival (PFS). Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is an experimental treatment of the AOC, introduced in clinical practice in order to improve cytoreduction rate and prolong survival. The aim of this study was to compare the survival and cytoreduction rate of NACT+IDS and PDS in patients with the AOC. Methods. This retrospective cohort study included patients with the AOC, separated into two groups. The first group treated with PDS had 59 patients, while the second group, treated with NACT + IDS, had 33 patients. Results. A lower rate of suboptimal cytoreduction (39.39%) was found in the NACT + IDS group than in the PDS group (57.63%). The percentage of complete cytoreduction was higher in patients treated with NACT + IDS (51.52%) than in those treated with PDS (38.98%). Nevertheless, median OS and PFS were not significantly different between the groups (p < 0.05). OS was 35 months and 31 months in the PDS and NACT + IDS groups, respectively. PFS was 16 months in the PDS and 19 months in the NACT + IDS group. Conclusion. Despite the higher rate of optimal debulking surgery after NACT+ IDS, survival of patients treated with method was not better than those treated with PDS. The decision for either NACT+IDS or PDS should be tailored to the individual patient.

1 January 2024 in Medicinski Pregled
Verified
Journal Article
Open access
PDF file
DKDunja Kokanov
Dunja Kokanov
TMTamara Maksimovic
Tamara Maksimovic
NSNemanja Stevanovic
Nemanja Stevanovic
SMSlobodan Maricic
Slobodan Maricic
SPSonja Lukac Pualic
Sonja Lukac Pualic
KSKristina Savic
Kristina Savic
Introduction. Ovarian cancer represents the deadliest gynecological malignancy. The aim of this study is to validate the predictive value of Cancer antigen-125 Elimination rate constant K score regarding progression-free survival among patients with Stage IIIc-IV high-grade serous ovarian cancer according to the International Federation of Gynecology and Obstetrics, treated with bevacizumab. Additionally, the study aims to determine the significance of a score in the assessment of progression-free survival in relation to operation status and disease stage. Material and Methods. The retrospective study was conducted at the Oncology Institute of Vojvodina and included 56 patients treated for high-grade serous ovarian cancer. The treatment protocol consisted of chemotherapy with paclitaxel and carboplatin, followed by bevacizumab maintenance therapy. The Cancer Antigen- 125 Elimination Rate Constant K score was calculated using three Cancer Antigen 125 tumor marker values. Based on this calculation, the score was dichotomized into favorabe (?1) and unfavorable (<1) groups. Results. The analysis of the score?s impact on progression-free survival revealed that patients with a score ?1 had longer mean survival time compared to a score <1 (19.4 vs 17.0 months). This difference was not statistically significant (p=0.549). The operation status in relation to a score was the only statistically significant factor with progression-free survival benefit (p=0.002). Conclusion. In our study, Cancer antigen- 125 Elimination rate constant K score did not emerge as a statistically significant prognostic factor for identifying patients most likely to benefit from bevacizumab. The operative status showed significant predictive value.

1 January 2025 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
MKMarijana Milovic Kovacevic
Marijana Milovic Kovacevic
MMMladen Marinkovic
Mladen Marinkovic
SMSlobodan Maricic
Slobodan Maricic
SSSuzana Stojanovic-Rundic
Suzana Stojanovic-Rundic
SRSandra S Radenkovic
Sandra S Radenkovic
Introduction: Standard therapy for patients with ovarian cancer involves cytoreductive surgery followed by platinum-based chemotherapy. Factors such as the stage of the disease at diagnosis, the histological type of the tumor, the size of the tumor and the presence of residual disease after cytoreductive surgery influence the prognosis of patients. Material and methods: This scientific paper presents a retrospective study in which the following parameters were analyzed by analyzing data obtained from the documentation of patients treated for ovarian cancer at the Institute of Oncology and Radiology of Serbia and the Institute of Oncology of Vojvodina: age of patients, period from last chemotherapy to disease progression, number of bevacizumab cycles received, disease stage, reasons for discontinuation of bevacizumab, type of surgery, and pathological verification of the disease. Results: We have shown that PFS is longer in the operated group (suboptimal operation) compared to those who were not operated (p < 0.05, Log-Rank test). There is no statistically significant difference in PFS between stages IIIc and IV, as determined by Log-Rank test. Additionally, in our research, there was no significant difference in the number of operated patients based on disease stage IIIc or IV (p = 0.361). Conclusions: Our data show that cytoreduction appears to confer a survival advantage in women with ovarian cancer treated with a combination of bevacizumab and chemotherapy. New studies should show whether the stage of the disease plays a significant role in the survival of patients with ovarian cancer.

Verified
Journal Article
Open access
PDF file
DNDragana Tomic Tomic Naglic
Dragana Tomic Tomic Naglic
MMMia Manojlović
Mia Manojlović
SPSlađana Pejaković
Slađana Pejaković
Nikolina VukovicNikolina Vukovic
Nikolina Vukovic
TGTeodor Grbić
Teodor Grbić
AMAndrijana Milankov
Andrijana Milankov
Obesity is characterized by chronic low-grade inflammation (meta-inflammation) and metabolic dysregulation. Adipose tissue acts as an immunometabolic organ, with macrophages playing a central role. This review examines inflammatory memory in adipose tissue, focusing on CD68+ macrophages and their role in cardiometabolic and cancer risk during weight cycling. (2) Narrative synthesis of evidence from immunology, obesitology, and oncology, with emphasis on macrophage polarization and signaling pathways. (3) Weight cycling induces persistent immune memory in adipose tissue, characterized by exaggerated macrophage responses upon weight regain. CD68+ macrophages contribute to extracellular matrix remodeling, tumor signaling, and metabolic dysfunction. Key mechanisms include PI3K/AKT/mTOR dysregulation, FOXO1/KLF10 axis impairment, and CREB-mediated transcription. This inflammatory memory promotes atherosclerosis progression, insulin resistance, and increased cancer risk, despite prior weight loss. (4) Macrophage-driven inflammatory memory represents a key mechanistic link between obesity, cardiometabolic disease, and cancer. Targeting meta-inflammation independent of body weight should be integral to future therapies.

1 January 2025
Verified
Journal Article
Closed access
TMTamara Maksimovic
Tamara Maksimovic
AMAljosa Mandic
Aljosa Mandic
DKDunja Kokanov
Dunja Kokanov
SMSlobodan Maricic
Slobodan Maricic
NSNemanja Stevanovic
Nemanja Stevanovic
BGBojana Gutic-Vukobrat
Bojana Gutic-Vukobrat
Introduction. Low-grade serous ovarian carcinoma is a distinct and relatively uncommon histologic subtype of epithelial ovarian cancer, characterized by unique biological and clinical features that differentiate from high-grade and other epithelial subtypes. Material and Methods. A comprehensive literature search was performed to identify interventional studies, systematic reviews, case reports, and meta-analyses published between 2010 and 2024, focusing on the diagnosis, management, and outcomes of low-grade serous ovarian carcinoma. Diagnosis. Ultrasound is the first-line imaging modality for evaluating ovarian and adnexal lesions. Computed tomography remains the preferred method for staging, treatment planning, and posttherapy monitoring, while magnetic resonance imaging is recommended for characterizing indeterminate adnexal masses or for evaluating extensive disease visualized on ultrasound or computed tomography. Clinical management. For patients with advanced-stage disease (FIGO stages II-IV), maximal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel remains the standard of care. Optimal cytoreduction is associated with significantly improved overall and progressionfree survival compared with suboptimal surgery. Given the intrinsic chemoresistance of low-grade serous ovarian carcinoma, primary cytoreductive surgery is generally favored over neoadjuvant chemotherapy. Emerging targeted therapies focusing on CDK4/6, MAPK, and PI3K/AKT/mTOR pathways, as well as hormonal treatments, are under investigation and have demonstrated encouraging preliminary results. Conclusion. The management of low-grade serous ovarian carcinoma increasingly necessitates an individualized, multidisciplinary approach. Future therapeutic strategies will likely integrate molecularly targeted and endocrine therapies with optimal cytoreductive surgery to improve outcomes for this chemoresistant and biologically distinct ovarian cancer subtype.

1 January 2023 in SCRIPTA MEDICA
Verified
Journal Article
Open access
PDF file
AMAljoša Mandić
Aljoša Mandić
NNNatasa Nikolic
Natasa Nikolic
SMSlobodan Maricic
Slobodan Maricic
BGBojana Gutić
Bojana Gutić
NSNemanja Stevanović
Nemanja Stevanović
BBBranka Bašica
Branka Bašica
Background/Aim: Geotropism of the human papillomavirus (HPV) represents the heterogeneous distribution of different genotypes worldwide. Aim of this study was to evaluate the prevalence of the HPV infection in women from Vojvodina, Serbia, according to cytological status and pathological changes of cervix - dysplasia and cancer. Methods: The research was conducted as a retrospective study at the Oncology Institute of Vojvodina and the Institute of Public Health of Vojvodina (IPHV). Data from the medical records of female patients treated for cervical intraepithelial neoplasia or cervical cancer at the Department of Gynaecology, Clinic for Surgical Oncology, Oncology Institute of Vojvodina in Sremska Kamenica in the period from 2016 to 2021 were used, as well as the laboratory findings of the IPHV for a group of patients with normal cytological results of the Papanikolau (PAPA) smear. Results: A total of 731 women, from 20 to 82 years of age, with different cytological results were enrolled. 567 samples were classified as NILM, while 164 samples belong to a group of abnormal histopathology (LSIL/HSIL/cervical cancer). The HPV genotyping assay was performed using the EUROArray HPV test to detect 30 HPV genotypes. In the overall number with normal cytological findings, HPV infection was verified in 242 (42.7 %) patients, of which 135 (55.8 %) were verified with high risk HPV, while 76 (31.4 %) were verified with a mixed group of HPV (Low risk/High risk HPV). Most prevalent genotypes were HPV 16, 31, 53, 51 and 18 in NILM cytological status. In the samples with the abnormal histopathology, the most prevalent genotypes were HPV 16, 33, 31 and 56, while 18 and 39 were equally verified. Genotype 16 was the most prevalent in the examined sample, with a higher prevalence in higher-grade histopathological findings: 18.8 % in LSIL, 31.9 % in HSIL and 75.0 % in cervical cancer samples. Infection with multiple associated genotypes of HPV was not correlated with histopathology. By comparing histopathological diagnosis and age, older patients had higher-grade lesions. Conclusion: Based on the estimated oncogenic potential of HPV genotypes as well as their prevalence in presented sample, it can be concluded that the nine-valent HPV vaccine for genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58 would have the potential to prevent HPV infection and the incidence of precancerous lesions and cervical cancer in about 85 % of women. Observing trends in the prevalence of HPV, especially HR HPV genotypes, can be important in the further strategy of applying secondary and primary prevention, as well as the application of HPV detection as part of co-testing or considering the introduction of HPV testing in the initial screening program.